Predictable signs of benign course of polypoidal choroidal vasculopathy: based upon the long-term observation of non-treated eyes

被引:12
|
作者
Okubo, Akiko [1 ]
Arimura, Noboru [1 ]
Abematsu, Noriko [1 ]
Sakamoto, Taiji [1 ]
机构
[1] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan
关键词
benign; clinical course; polypoidal choroidal vasculopathy; predictable sign; visual prognosis; INTRAVITREAL BEVACIZUMAB AVASTIN; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
D O I
10.1111/j.1755-3768.2009.01850.x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To find predictable signs of benign polypoidal choroidal vasculopathy (PCV). Methods: Medical records of 13 eyes from 12 patients who were followed up for 5 years or longer without treatment among 258 consecutive patients with PCV were reviewed retrospectively. The main outcomes measured were best corrected visual acuity (BCVA) and fundus findings during the follow-up period. Results: The average age at presentation was 68 years, and the average follow-up period after diagnosis was 80 months (range, 62-119 months). The initial mean logarithmic value of the minimal angle of resolution (logMAR) BCVA was 0.28 +/- 0.26, and the final mean logMAR BCVA was 0.62 +/- 0.72. The difference in the logMAR BCVA values between the two points was not statistically significant (p > 0.05). The trend of change from baseline at 2-year follow-up was consistent with those at 5-year follow-up in nine eyes. Fundus findings at the initial examination were classified into two patterns: (i) reddish-orange nodules and detachment of the retinal pigment epithelium with/without detachment of the neurosensory retina (nine eyes); (ii) reddish-orange nodules alone, or nodules and small subretinal haemorrhage (four eyes). In the eyes with the first pattern, clinical course and visual prognosis were variable. An absence of hard exudates could be a sign to maintain a benign clinical course or stable vision with this pattern. The eyes with the second pattern took a benign clinical course with stable vision. Conclusions: There is certainly a group of PCV eyes with a benign prognosis. Considering the huge cost and risk of current therapies, the initial ocular findings could be deciding factors that determine the necessity for further treatment.
引用
收藏
页码:e107 / e114
页数:8
相关论文
共 35 条
  • [21] Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
    Jain, Prashant
    Anantharaman, Giridhar
    Gopalakrishnan, Mahesh
    Goyal, Anubhav
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2018, 66 (08) : 1119 - 1127
  • [22] Impact of sub-foveal choroidal thickness on clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy
    Venkatesh, Ramesh
    Gadde, Santosh Gopi Krishna
    Pereira, Arpitha
    Singh, Vivek
    Sangai, Sajjan
    Sridharan, Akhila
    Bavaharan, Bharathi
    Jain, Nimesh
    Yadav, Naresh Kumar
    INTERNATIONAL OPHTHALMOLOGY, 2021, 41 (01) : 87 - 97
  • [23] Combined Photodynamic Therapy With Intravitreal Bevacizumab Injections for Polypoidal Choroidal Vasculopathy: Long-term Visual Outcome
    Kang, Hae Min
    Koh, Hyoung Jun
    Lee, Christopher Seungkyu
    Lee, Sung Chul
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 157 (03) : 598 - 606
  • [24] Long-term Visual Outcome and Prognostic Factors After Intravitreal Ranibizumab Injections for Polypoidal Choroidal Vasculopathy
    Kang, Hae Min
    Koh, Hyoung Jun
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 156 (04) : 652 - 660
  • [25] Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy
    Azuma, Keiko
    Okubo, Atsushi
    Nomura, Yoko
    Zhou, Hanpeng
    Terao, Ryo
    Hashimoto, Yohei
    Asano, Kimiko Shimizu
    Azuma, Kunihiro
    Inoue, Tatsuya
    Obata, Ryo
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [26] Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration
    Hyeon Cheol Roh
    Sang Jin Kim
    Se Woong Kang
    Jun Soo Eun
    Kyung Jun Choi
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 83 - 92
  • [27] Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
    Jae Hui Kim
    Jong Woo Kim
    Chul Gu Kim
    Dong Won Lee
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258 : 1677 - 1685
  • [28] Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up
    Tang, Jiyang
    Han, Xinyao
    Tang, Ran
    Li, Mengyang
    Wang, Zongyi
    Zhao, Mingwei
    Qu, Jinfeng
    BMC OPHTHALMOLOGY, 2022, 22 (01)
  • [29] Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up
    Jiyang Tang
    Xinyao Han
    Ran Tang
    Mengyang Li
    Zongyi Wang
    Mingwei Zhao
    Jinfeng Qu
    BMC Ophthalmology, 22
  • [30] Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
    Kim, Jae Hui
    Kim, Jong Woo
    Kim, Chul Gu
    Lee, Dong Won
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (08) : 1677 - 1685